DnB Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.4M | Sell |
114,940
-13,172
| -10% | -$1.66M | 0.06% | 209 |
|
|
2025
Q1 | $14.2M | Buy |
128,112
+9,885
| +8% | +$1.09M | 0.07% | 200 |
|
|
2024
Q4 | $16.1M | Buy |
118,227
+3,500
| +3% | +$478K | 0.07% | 194 |
|
|
2024
Q3 | $13.2M | Buy |
114,727
+39,781
| +53% | +$4.58M | 0.06% | 214 |
|
|
2024
Q2 | $10.3M | Buy |
74,946
+10,998
| +17% | +$1.51M | 0.05% | 220 |
|
|
2024
Q1 | $8.82M | Sell |
63,948
-1,895
| -3% | -$261K | 0.05% | 243 |
|
|
2023
Q4 | $8.68M | Sell |
65,843
-14,189
| -18% | -$1.87M | 0.05% | 265 |
|
|
2023
Q3 | $9M | Sell |
80,032
-3,645
| -4% | -$410K | 0.05% | 246 |
|
|
2023
Q2 | $7.89M | Sell |
83,677
-12,440
| -13% | -$1.17M | 0.05% | 279 |
|
|
2023
Q1 | $9.73M | Buy |
96,117
+9,456
| +11% | +$957K | 0.06% | 239 |
|
|
2022
Q4 | $10.4M | Sell |
86,661
-1,105
| -1% | -$132K | 0.07% | 214 |
|
|
2022
Q3 | $9.32M | Sell |
87,766
-38,559
| -31% | -$4.1M | 0.07% | 221 |
|
|
2022
Q2 | $12.3M | Sell |
126,325
-8,829
| -7% | -$861K | 0.09% | 195 |
|
|
2022
Q1 | $12.7M | Sell |
135,154
-5,469
| -4% | -$513K | 0.08% | 205 |
|
|
2021
Q4 | $12M | Buy |
140,623
+22,344
| +19% | +$1.9M | 0.07% | 208 |
|
|
2021
Q3 | $11.3M | Sell |
118,279
-19,944
| -14% | -$1.91M | 0.07% | 208 |
|
|
2021
Q2 | $13.5M | Buy |
138,223
+19,454
| +16% | +$1.89M | 0.09% | 178 |
|
|
2021
Q1 | $11.6M | Buy |
118,769
+83,562
| +237% | +$8.13M | 0.08% | 187 |
|
|
2020
Q4 | $3.37M | Buy |
35,207
+22,831
| +184% | +$2.19M | 0.03% | 353 |
|
|
2020
Q3 | $1.19M | Hold |
12,376
| – | – | 0.01% | 505 |
|
|
2020
Q2 | $1.51M | Buy |
12,376
+1,477
| +14% | +$180K | 0.02% | 434 |
|
|
2020
Q1 | $943K | Sell |
10,899
-930
| -8% | -$80.5K | 0.01% | 493 |
|
|
2019
Q4 | $1.27M | Buy |
+11,829
| New | +$1.27M | 0.01% | 544 |
|